Multidentate 18F-polypegylated styrylpyridines As imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA)

Journal of Medicinal Chemistry

Volumn 54, Issue 23, 2011, Pages 8085-8098

  Zha, Zhihao ^a   Choi, Seok Rye ^a   Ploessl, Karl ^a   Lieberman, Brian P ^a   Qu, Wenchao ^a   Hefti, Franz ^b   Mintun, Mark ^b   Skovronsky, Daniel ^a,b   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 [DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 OL F 18; 1,3 [DI[2 [2 [2 [2 [5 [4 [TERT-BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 OL F 18; 1,3 DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 OL F 18; 14 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY] 3,6,9,12 TETRAOXATETRADECYL 4 METHYLBENZENESULFONATE F 18; 17 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY] 3,6,9,12,15 PENTAOXAHEPTADECYL 4 METHYLBENZENESULFONATE F 18; 2 (1,3 DIBROMOPROPAN 2 YLOXY)TETRAHYDRO 2H PYRAN F 18; 2 (2 FLUOROETHOXY) 1,3 [DI[2 [2 [2 [5 [4 (METHYLAMINO)STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXYPROPANE F 18; 2 (2 FLUOROETHOXY) 1,3 [DI[2 [2 [2 [5 [4 (METHYLAMINO)STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPANE F 18; 2 (2 FLUOROETHOXY) 1,3 DI[2 [2 [2 [5 [4 (METHYLAMINO)STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]PROPANE F 18; 2 (TETRAHYDRO 2H PYRAN 2 YLOXY)PROPANE 1,3 DIOL F 18; 2 (TETRAHYDRO 2H PYRAN 2 YLOXY)PROPANE 1,3 DIYL DIACETATE F 18; 2 [1,3 [DI [2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]TETRAHYDRO 2H PYRAN F 18; 2 [1,3 [DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]TETRAHYDRO 2H PYRAN F 18; 2 [1,3 DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]ETHANOL F 18; 2 [1,3 DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]TETRAHYDRO 2H PYRAN F 18; 2 [2 [1,3 [DI [2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]ETHOXY]TETRAHYDRO 2H PYRAN F 18; 2 [2 [1,3 DI [2 [2 [2 [2 [5 [4 TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]ETHANOL F 18; 2 [2 [1,3 DI[2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]PROPAN 2 YLOXY]ETHOXY]TETRAHYDRO 2H PYRAN F 18; 2 [2 [2 (2 FLUOROETHOXY)ETHOXY]ETHOXY] N,N BIS[14 [5 [4 (METHYLAMINO)STYRYL]PYRIDIN 2 YLOXY] 2 OXO 6,9,12 TRIOXA 3 AZATETRADECYL]ACETAMIDE F 18; 2 [2 [2 (5 IODOPYRIDIN 2 YLOXY)ETHOXY]ETHOXY]ETHANOL F 18; 2 [2 [2 [2 (5 IODOPYRIDIN 2 YLOXY)ETHOXY]ETHOXY]ETHOXY]ETHANOL F 18; 2 [2 [2 [2 [5 [4 [TERT BUTOXYCARBONYL(METHYL)AMINO]STYRYL]PYRIDIN 2 YLOXY]ETHOXY]ETHOXY]ETHOXY]ETHYL 4 METHYLBENZENESULFONATE F 18; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; STYRYLPYRIDINE DERIVATIVE F 18; TERT BUTYL 4 [2 [6 [2 [2 [2 (2 HYDROXYETHOXY)ETHOXY]ETHOXY]ETHOXY]PYRIDIN 3 YL]VINYL]PHENYL(METHYL)CARBAMATE F 18; TERT BUTYL 4 VINYLPHENYLCARBAMATE F 18; TERT BUTYL 4, 2 [6 [2 [2 [2 (2 HYDROXYETHOXY)ETHOXY]ETHOXY]PYRIDIN 3 YL]VINYL]PHENYL(METHYL)CARBAMATE F 18; TERT BUTYL METHYL(4 VINYLPHENYL)CARBAMATE F 18; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BETA AMYLOID PLAQUE; BINDING AFFINITY; BLOOD VESSEL WALL; BRAIN BLOOD VESSEL; DRUG SPECIFICITY; DRUG UPTAKE; HUMAN; HUMAN TISSUE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; VASCULAR AMYLOIDOSIS;

AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; FLUORINE RADIOISOTOPES; HUMANS; MICE; MICE, INBRED ICR; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; TISSUE DISTRIBUTION;

EID: 82555185536     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2009106     Document Type: Article

References (47)

1. Soontornniyomkij, V.; Choi, C.; Pomakian, J.; Vinters, H. V. High-definition characterization of cerebral beta-amyloid angiopathy in Alzheimer's disease Hum. Pathol. 2010, 41, 1601-1608
2. Fisher, M.; French, S.; Ji, P.; Kim, R. C. Cerebral microbleeds in the elderly: a pathological analysis Stroke 2010, 41, 2782-2785
3. Cordonnier, C. Brain microbleeds: more evidence, but still a clinical dilemma Curr. Opin. Neurol. 2011, 24, 69-74
4. Altmann-Schneider, I.; Trompet, S.; de Craen, A. J.; van Es, A. C.; Jukema, J. W.; Stott, D. J.; Sattar, N.; Westendorp, R. G.; van Buchem, M. A.; van der Grond, J. Cerebral microbleeds are predictive of mortality in the elderly Stroke 2011, 42, 638-644
5. Poels, M. M.; Ikram, M. A.; van der Lugt, A.; Hofman, A.; Krestin, G. P.; Breteler, M. M.; Vernooij, M. W. Incidence of cerebral microbleeds in the general population: the Rotterdam scan study Stroke 2011, 42, 656-661
6. Dierksen, G. A.; Skehan, M. E.; Khan, M. A.; Jeng, J.; Nandigam, R. N.; Becker, J. A.; Kumar, A.; Neal, K. L.; Betensky, R. A.; Frosch, M. P.; Rosand, J.; Johnson, K. A.; Viswanathan, A.; Salat, D. H.; Greenberg, S. M. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy Ann. Neurol. 2010, 68, 545-548
7. Weller, R. O.; Boche, D.; Nicoll, J. A. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy Acta Neuropathol. 2009, 118, 87-102
8. Weller, R.; Preston, S.; Subash, M.; Carare, R. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Alzheimers Res. Ther. 2009, 1, 6
9. Attems, J.; Jellinger, K. A.; Lintner, F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy Acta Neuropathol. 2005, 110, 222-231
10. Attems, J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms Acta Neuropathol. 2005, 110, 345-359
11. Attems, J.; Lintner, F.; Jellinger, K. A. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology Acta Neuropathol. 2004, 107, 283-291
12. Jellinger, K. A.; Attems, J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease J. Neurol. Sci. 2005, 229-230, 37-41
13. Jack, C. R., Jr.; Wiste, H. J.; Vemuri, P.; Weigand, S. D.; Senjem, M. L.; Zeng, G.; Bernstein, M. A.; Gunter, J. L.; Pankratz, V. S.; Aisen, P. S.; Weiner, M. W.; Petersen, R. C.; Shaw, L. M.; Trojanowski, J. Q.; Knopman, D. S. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 2010, 133, 3336-3348
14. Rinne, J.; Brooks, D.; Rossor, M.; Fox, N.; Bullock, R.; Klunk, W.; Mathis, C.; Blennow, K.; Barakos, J.; Okello, A.; Rodriguez Martinez de Liano, S.; Liu, E.; Koller, M.; Gregg, K.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol. 2010, 9, 363-372
15. Weiner, M.; Aisen, P.; Jack, C., Jr.; Jagust, W.; Trojanowski, J.; Shaw, L.; Saykin, A.; Morris, J.; Cairns, N.; Beckett, L.; Toga, A.; Green, R.; Walter, S.; Soares, H.; Snyder, P.; Siemers, E.; Potter, W.; Cole, P.; Schmidt, M. The Alzheimer's disease neuroimaging initiative: progress report and future plans Alzheimer's Dementia 2010, 6, 202-211.e7
16. Ikonomovic, M. D.; Klunk, W. E.; Abrahamson, E. E.; Mathis, C. A.; Price, J. C.; Tsopelas, N. D.; Lopresti, B. J.; Ziolko, S.; Bi, W.; Paljug, W. R.; Debnath, M. L.; Hope, C. E.; Isanski, B. A.; Hamilton, R. L.; Dekosky, S. T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 2008, 131, 1630-1645
17. Mok, V.; Leung, E.; Chu, W.; Chen, S.; Wong, A.; Xiong, Y.; Lam, W.; Ho, C.; Wong, K. Pittsburgh compound B binding in poststroke dementia J. Neurol. Scie. 2010, 290, 135-137
18. Ly, J.; Donnan, G.; Villemagne, V.; Zavala, J.; Ma, H.; O'Keefe, G.; Gong, S.; Gunawan, R.; Saunder, T.; Ackerman, U.; Tochon-Danguy, H.; Churilov, L.; Phan, T.; Rowe, C. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage Neurology 2010, 74, 487-493
19. Johnson, K. A.; Gregas, M.; Becker, J. A.; Kinnecom, C.; Salat, D. H.; Moran, E. K.; Smith, E. E.; Rosand, J.; Rentz, D. M.; Klunk, W. E.; Mathis, C. A.; Price, J. C.; Dekosky, S. T.; Fischman, A. J.; Greenberg, S. M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann. Neurol. 2007, 62, 229-234
20. Wong, D.; Rosenberg, P.; Zhou, Y.; Kumar, A.; Raymont, V.; Ravert, H.; Dannals, R.; Nandi, A.; Brasic, J.; Ye, W.; Hilton, J.; Lyketsos, C.; Kung, H.; Joshi, A.; Skovronsky, D.; Pontecorvo, M. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) J. Nucl. Med. 2010, 51, 913-920
21. Kung, H.; Choi, S.; Qu, W.; Zhang, W.; Skovronsky, D. (18)F Stilbenes and Styrylpyridines for PET Imaging of Abeta Plaques in Alzheimer's Disease: A Miniperspective J. Med. Chem. 2009, 53, 933-941
22. Choi, S.; Golding, G.; Zhuang, Z.; Zhang, W.; Lim, N.; Hefti, F.; Benedum, T.; Kilbourn, M.; Skovronsky, D.; Kung, H. Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain J. Nucl. Med. 2009, 50, 1887-1894
23. Zhang, W.; Kung, M.; Oya, S.; Hou, C.; Kung, H. (18)F-labeled styrylpyridines as PET agents for amyloid plaque imaging Nucl. Med. Biol. 2007, 34, 89-97
24. Clark, C. M.; Schneider, J. A.; Bedell, B. J.; Beach, T. G.; Bilker, W. B.; Mintun, M. A.; Pontecorvo, M. J.; Hefti, F.; Carpenter, A. P.; Flitter, M. L.; Krautkramer, M. J.; Kung, H. F.; Coleman, R. E.; Doraiswamy, P. M.; Fleisher, A. S.; Sabbagh, M. N.; Sadowsky, C. H.; Reiman, E. P.; Zehntner, S. P.; Skovronsky, D. M. Use of florbetapir-PET for imaging beta-amyloid pathology JAMA, J. Am. Med. Assoc. 2011, 305, 275-283
25. O'Keefe, G.; Saunder, T.; Ng, S.; Ackerman, U.; Tochon-Danguy, H.; Chan, J.; Gong, S.; Dyrks, T.; Lindemann, S.; Holl, G.; Dinkelborg, L.; Villemagne, V.; Rowe, C. Radiation Dosimetry of {beta}-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 J. Nucl. Med. 2009, 50, 309-315
26. Rowe, C.; Ackerman, U.; Browne, W.; Mulligan, R.; Pike, K.; O'Keefe, G.; Tochon-Danguy, H.; Chan, G.; Berlangieri, S.; Jones, G.; Dickinson-Rowe, K.; Kung, H.; Zhang, W.; Kung, M.; Skovronsky, D.; Dyrks, T.; Holl, G.; Krause, S.; Friebe, M.; Lehman, L.; Lindemann, S.; Dinkelborg, L.; Masters, C.; Villemagne, V. Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol. 2008, 7, 129-135
27. Zhang, W.; Oya, S.; Kung, M.; Hou, C.; Maier, D.; Kung, H. H. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain Nucl. Med. Biol. 2005, 32, 799-809
28. Zhang, W.; Oya, S.; Kung, M.; Hou, C.; Maier, D.; Kung, H. F-18 Stilbenes as PET Imaging Agents for Detecting beta-Amyloid Plaques in the Brain J. Med. Chem. 2005, 48, 5980-5988
29. Koole, M.; Lewis, D.; Buckley, C.; Nelissen, N.; Vandenbulcke, M.; Brooks, D.; Vandenberghe, R.; Van Laere, K. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging J. Nucl. Med. 2009, 50, 818-822
30. Nelissen, N.; Van Laere, K.; Thurfjell, L.; Owenius, R.; Vandenbulcke, M.; Koole, M.; Bormans, G.; Brooks, D. J.; Vandenberghe, R. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease J. Nucl. Med. 2009, 50, 1251-1259
31. Thomas, B. A.; Erlandsson, K.; Modat, M.; Thurfjell, L.; Vandenberghe, R.; Ourselin, S.; Hutton, B. F. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1104-1119
32. Vandenberghe, R.; Van Laere, K.; Ivanoiu, A.; Salmon, E.; Bastin, C.; Triau, E.; Hasselbalch, S.; Law, I.; Andersen, A.; Korner, A.; Minthon, L.; Garraux, G.; Nelissen, N.; Bormans, G.; Buckley, C.; Owenius, R.; Thurfjell, L.; Farrar, G.; Brooks, D. (18)F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann. Neurol. 2010, 68, 319-329
33. Vallabhajosula, S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid Semin. Nucl. Med. 2011, 41, 283-299
34. Jureus, A.; Swahn, B.; Sandell, J.; Jeppsson, F.; Johnson, A.; Johnstrom, P.; Neelissen, J.; Sunnemark, D.; Farde, L.; Svensson, S. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand J. Neurochem. 2010, 114, 784-794
35. Pajk, S.; Pecar, S. Synthesis of novel amphiphilic spin probes with the paramagnetic doxyl group in the polar region Tetrahedron 2009, 65, 659-665
36. Adamsen, T. C. H.; Grierson, J. R.; Krohn, K. A. A new synthesis of the labeling precursor for [18F]-fluoromisonidazole J. Labelled Compd. Radiopharm. 2005, 48, 923-927
37. Qu, W.; Kung, M.; Hou, C.; Benedum, T.; Kung, H. Novel styrylpyridines as probes for SPECT imaging of amyloid plaques J. Med. Chem. 2007, 50, 2157-2165
38. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. Engl. 2002, 41, 2596-2599
39. Del Valle, J.; Duran-Vilaregut, J.; Manich, G.; Casadesus, G.; Smith, M. A.; Camins, A.; Pallas, M.; Pelegri, C.; Vilaplana, J. Early amyloid accumulation in the hippocampus of SAMP8 mice J. Alzheimer's Dis. 2010, 19, 1303-1315
40. Beckmann, N.; Gerard, C.; Abramowski, D.; Cannet, C.; Staufenbiel, M. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy J. Neurosci. 2011, 31, 1023-1031
41. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S. S.; Chen, X. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice Bioconjugate Chem. 2005, 16, 1433-1441
42. Liu, Z.; Shi, J.; Jia, B.; Yu, Z.; Liu, Y.; Zhao, H.; Li, F.; Tian, J.; Chen, X.; Liu, S.; Wang, F. Two (90)Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy Mol. Pharm. 2011, 8, 591-599
43. Dijkgraaf, I.; Yim, C. B.; Franssen, G. M.; Schuit, R. C.; Luurtsema, G.; Liu, S.; Oyen, W. J.; Boerman, O. C. PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 128-137
44. Dijkgraaf, I.; Kruijtzer, J. A.; Liu, S.; Soede, A. C.; Oyen, W. J.; Corstens, F. H.; Liskamp, R. M.; Boerman, O. C. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 267-273
45. Kiessling, F.; Huppert, J.; Zhang, C.; Jayapaul, J.; Zwick, S.; Woenne, E. C.; Mueller, M. M.; Zentgraf, H.; Eisenhut, M.; Addadi, Y.; Neeman, M.; Semmler, W. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment Radiology 2009, 253, 462-469
46. Li, F.; Liu, J.; Jas, G. S.; Zhang, J.; Qin, G.; Xing, J.; Cotes, C.; Zhao, H.; Wang, X.; Diaz, L. A.; Shi, Z. Z.; Lee, D. Y.; Li, K. C.; Li, Z. Synthesis and evaluation of a near-infrared fluorescent non-peptidic bivalent integrin alpha(v)beta(3) antagonist for cancer imaging Bioconjugate Chem. 2010, 21, 270-278
47. Li, F.; Jas, G. S.; Qin, G.; Li, K.; Li, Z. Synthesis and evaluation of bivalent, peptidomimetic antagonists of the alphavbeta3 integrins Bioorg. Med. Chem. Lett. 2010, 20, 6577-6580